Revolutionary Blood Test Detects Cancer Recurrence with AI-Powered Precision
Staff Editor OneCell Diagnostics Revolutionizes Cancer Recurrence Detection with Innovative Blood-Based Biopsy
In a world where cancer is projected to affect over 35 million people by 2050, OneCell Diagnostics, a genomics-based startup, is making significant strides in precision oncology. The company aims to reduce cancer recurrence through its proprietary technology, addressing the critical need for effective diagnostic solutions in cancer prevention.
OneCell Diagnostics has developed a groundbreaking blood-based biopsy testing method for detecting cancer recurrence. Unlike traditional methods such as PET CT scans and MRIs, this innovative approach utilizes circulating tumor cells, providing a less invasive and potentially more accurate diagnostic tool.
The diagnostic process involves collecting blood samples at home by a phlebotomist. These samples undergo analysis using scientific methods and artificial intelligence to predict cancer recurrence. OneCell’s True-Single-Cell-Multi-omics approach offers extensive diagnostic information, potentially revolutionizing cancer care.
To aid oncologists in interpreting test reports, OneCell has developed the iCare app. This tool combines cell science and data science, making precision oncology more accessible globally. The company’s proprietary glass bead technology uses antibodies to filter circulating tumor cells from blood, offering pan-cancer analysis for solid tumors such as breast, lung, and colon cancers.
OneCell Diagnostics is strategically targeting the recurrence patient market to avoid high-risk areas associated with first-time cancer diagnoses. The company competes with established players like Guardant Health and Natera, offering affordable and precise diagnostics.
Currently operating under a B2B2C model in India, OneCell plans to expand into the U.S. market with local biomarker partners. The company’s early success in India has provided valuable data and partnerships, positioning it for future growth.
OneCell has secured strategic collaborations with top hospitals and academic institutions, raising $16 million in Series A funding. Nobel Laureate James Rothman has joined the board, further validating the company’s potential impact on cancer diagnostics.
Looking ahead, OneCell Diagnostics aims to reach over 1,000 oncologists and a million patients. With plans to expand into the U.S. and scale operations in India, the company is poised to make a significant impact in the fight against cancer recurrence.
